Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
SALT LAKE CITY and FREMONT, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc., a leader in advanced genomics for precision oncology, (Nasdaq: PSNL) today announced a non-exclusive collaboration through which Myriad will market the Personalis® ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners who use the MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx cancer tests.
“An increasing number of our companion diagnostic pharmaceutical partners are requesting complementary whole exome and whole transcriptome testing on their patients’ tumors,” said Paul Diaz, President and CEO, Myriad Genetics. “Our goal is to provide full menu access to our customers and we are pleased to leverage Personalis’ high quality assays to expand our offering.”
Personalis’ ImmunoID NeXT platform is the most discriminating platform to power drug development biomarker efforts and has been utilized by the top 20 global bio-pharma companies. It provides high-quality exome/transcriptome assays for cancer FFPE samples.
“A key pillar of our strategy is to expand our reach through commercial partnerships and this new collaboration with Myriad is an exciting milestone of our progress,” said Chris Hall, CEO and President of Personalis.
Financial details of the partnership were not disclosed.
About Myriad Genetics, Inc.
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding cre from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).
Personalis Forward-Looking Statements
Myriad Forward-Looking Statements
Personalis Investor Contact:
Personalis Media Contact:
Myriad Genetics Media Contact:
Myriad Genetics Investor Contact:
Registration Counters Open
Grand Opening Reception in Expo Hall
Generative AI Expo #TECHSUPERSHOW Booth Crawl